ArcBest Corp: Stifel cuts target price to $168 from $185
ARCB•Stifel cut its target price for ArcBest to $168 from $185.
Related News
Xenon Pharmaceuticals: Leerink Partners cuts target price to $60 from $70
XENE•
X4 Pharmaceuticals secures up to $150 million senior debt facility with K2 HealthVentures
XFOR•
Installed Building Products: Truist Securities cuts target price to $160 from $200
IBP•
Clearmind says Japan publishes patent application on 3-MMC-based dyskinesia treatment
CMND•
Auddia posts CEO letter updating on proposed merger with Thramann Holdings
AUUD•